Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

33.15 +0.81 (+2.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 354,750
Open 32.72
Bid (Size) 33.15 (2)
Ask (Size) 33.19 (9)
Prev. Close 32.34
Today's Range 32.33 - 33.20
52wk Range 25.53 - 40.28
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-9.0%
-9.0%
1 Month
+7.1%
+7.1%
3 Month
+3.4%
+3.4%
6 Month
-10.8%
-10.8%
1 Year
+22.1%
+22.1%

More News

Read More
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For May 6, 2025
Via Benzinga
3 Cash-Heavy Stocks in the Doghouse
Via StockStory
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
3 Dawdling Stocks with Mounting Challenges
Via StockStory
3 Stocks Under $50 That Concern Us
Via StockStory
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations
Via StockStory
Topics Earnings
Exposures Financial
Supernus Announces First Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview
Via Benzinga
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Via StockStory
3 Healthcare Stocks with Mounting Challenges
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings?
Via StockStory
Topics Stocks Supply Chain
Exposures Supply Chain US Equities
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.
Via Investor's Business Daily
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 33.15
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 06/06/25 04:00 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 1.76B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.